Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,084 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: HIV Infections
Interventions: Nevirapine XR, Nevirapine IR; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 11
States / cities: Beverly Hills, California • Long Beach, California • Los Angeles, California + 6 more

Conditions: Epilepsy
Interventions: retigabine/ezogabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 29 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more

Conditions: Eosinophilic Esophagitis
Interventions: APT-1011, Placebo oral tablet; Drug
Lead sponsor: Ellodi Pharmaceuticals, LP; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Crohn's Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 54
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Ianalumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 25
States / cities: Anniston, Alabama • Burbank, California • La Palma, California + 22 more

Conditions: RLS
Interventions: HORIZANT 600 mg; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 11
States / cities: Redwood City, California • San Diego, California • Gulf Breeze, Florida + 8 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: riliprubart, Placebo, IVIg; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 32
States / cities: Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 28 more

Conditions: Wilson Disease
Interventions: ALXN1840; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 1 more

Conditions: Advanced Solid Tumors
Interventions: JI-101; Drug
Lead sponsor: Jubilant Innovation Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cholesterol Ester Storage Disease (CESD), Lysosomal Acid Lipase Deficiency, LAL-Deficiency
Interventions: sebelipase alfa; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 5
States / cities: Eureka, California • Sacramento, California • San Francisco, California + 2 more

Conditions: Depression, Palliative Care, Cancer, Mental Disorder
Interventions: Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension, Pulmonary
Interventions: Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator; Drug
Lead sponsor: Actelion; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: 16P11.2 Deletion Syndrome
Interventions: Arbaclofen, Placebo oral tablet; Drug
Lead sponsor: Clinical Research Associates, LLC; Other
Eligibility: 5 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas + 1 more

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: Pelacarsen (TQJ230); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 5,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 120
States / cities: Andalusia, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more

Conditions: Post Operative Pain, Acute, Bariatric Surgery Candidate, Postoperative Pain
Interventions: ZYNRELEF 200Mg-6Mg Extended-Release Solution; Drug
Lead sponsor: Dr. Yannis Raftopoulos; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Holyoke, Massachusetts

Conditions: Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 72
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more

Conditions: WHIM Syndrome
Interventions: X4P-001; Drug
Lead sponsor: X4 Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Partial Onset Seizures
Interventions: BGG492; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 66 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas

Conditions: Gaucher Disease, Type 1
Interventions: VPRIV®; Biological
Lead sponsor: Shire; Industry
Eligibility: 2 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 10
States / cities: Los Angeles, California • Oakland, California • Atlanta, Georgia + 7 more

Conditions: Dravet Syndrome
Interventions: ZX008 (Fenfluramine Hydrochloride); Drug
Lead sponsor: Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; Industry
Eligibility: 2 Years to 35 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Aurora, Colorado

Conditions: Lung Transplant
Interventions: Cyclosporine Inhalation Solution (CIS); Drug
Lead sponsor: APT Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 12 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: LPCN 1144; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Roseville, California • Ocoee, Florida • Las Vegas, Nevada + 6 more

Conditions: Solid Tumors, NHL
Interventions: KPT-9274, Niacin ER, Nivolumab; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Rosacea
Interventions: Anatabloc Cream, Placebo Cream; Other
Lead sponsor: Rock Creek Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Bradenton, Florida • New Orleans, Louisiana • New York, New York

Search by objective public record fields.

Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients

Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

ZYNRELEF® for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy

An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Phase II BGG492 Capsule Extension for Partial Epilepsy

An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome

CIS001 Extension Study of Cyclosporine Inhalation Solution

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea